RxDoctor Payments Data

John Scherer, MD

Gastroenterology · Columbus, OHNPI 1861653701

Payments from drug & device makers

$3,298in general payments, 2019–2025

Across 27 payments — averaging $122.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ovesco Endoscopy USA, Inc.$2K
  • Boston Scientific$866
  • AbbVie$269
  • Pfizer$111
  • Amgen$104
  • Sanofi$97
  • plus $44 from 2 others

What the payments were for

  • Travel & lodging$2,20067%
  • Food & beverage$1,09833%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Ovesco Endoscopy USA, Inc.1$1,807
Boston Scientific18$866
AbbVie3$269
Pfizer1$111
Amgen1$104
Sanofi1$97
Fujifilm Healthcare Americas Corporation1$26
Ferring Pharmaceuticals Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,298 in reported general payments places this provider in the 50th percentile of 657 gastroenterology providers in Ohio.

See all gastroenterology providers in Ohio

Medicare billing

Part B allowed, 2024
$100,795
Medicare patients
490
Services billed
778

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab12$166,983
LinzessLinaclotide17$16,953
Mesalamine24$12,449
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg331$5,941
Esomeprazole Magnesium57$3,506
Balsalazide Disodium16$2,076
Colestipol Hcl28$2,064
Omeprazole129$1,769
Pantoprazole Sodium43$962
Peg3350-Sod Sul-Nacl-Kcl-Asb-CPeg3350/Sod Sul/Nacl/Kcl/Asb/C11$923
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates13$831
Famotidine43$554
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl36$470
Dicyclomine Hcl21$245
Ondansetron Hcl12$229

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$269$16,95317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 657 gastroenterology providers in Ohio.

Other gastroenterology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →